Host: Stephen M. Cohen, MD, FACOG

Guest: Thomas C. Wright, Jr., MD

Cervical cancer screening (CCS) methods include cytology alone, use of primary high-risk HPV testing alone, and co-testing. Regardless of the screening approach used, effective triage tests are needed to decide who among the presumptive positive women should receive further diagnostic evaluation. Unfortunately, current approaches to triage can complicate matters and the results can be more confusing than constructive.

Our discussion today will focus on how to address the unmet needs associated with current CCS triage options and the diagnostic benefits provided by p16/Ki-67 dual-staining cytology in CCS triage to alleviate diagnostic uncertainty within clinical practice.